Download PDF
TumorDiagnostik & Therapie 2014; 35(5): 268-273
DOI: 10.1055/s-0034-1369212
Schwerpunkt: Gastrointestinale Stromatumoren
Georg Thieme Verlag KG Stuttgart · New York

Übersicht – Therapie gastrointestinaler Stromatumoren

K. Heißner
,
H.-G. Kopp
Further Information

Publication History

Publication Date:
19 August 2014 (online)

Also available at
    Permissions and Reprints

Die Therapie gastrointestinaler Stromatumoren (GIST) ist einer der ersten Erfolge der Medizin auf dem Gebiet der zielgerichteten molekularen Medizin. Die Erkenntnis, dass onkogene Mutationen der Rezeptor-Tyrosinkinase c-KIT und PDGFRα zum malignen Wachstum der Cajal-Zellen führt und durch den Einsatz selektiver Tyrosinkinaseinhibitoren (TKI) effektiv gehemmt werden kann, stellte einen der ersten Meilensteine auf dem Weg zu einer individualisierten Krebstherapie dar. Heute sind wir in der Lage anhand radiologischer, histologischer und molekularbiologischer Kriterien die Notwendigkeit einer adjuvanten Therapie nach kompletter Resektion abschätzen zu können. Zudem sind bestimmte Mutationen auch prädiktiv hinsichtlich Ansprechen und Dosis von TKI.

Im Fall primär metastasierter oder rezidivierter GIST lag das mediane Überleben von Patienten vor der Aufklärung des molekularen Pathomechanismus bei 10–20 Monaten [1]. Seit der Verfügbarkeit von TKIs konnte das mediane Überleben auf 51–57 Monate verlängert werden [2],[3]. Auf der diesjährigen ASCO-Jahrestagung wurden Langzeitüberlebensdaten von Studienpatienten in palliativer Situation unter Therapie mit Tyrosinkinaseinhibitoren publiziert [4]. Die Nachbeobachtung von 695 Patienten dokumentiert ein Überleben in 26% und 22% der Patienten nach 8 bzw. 10 Jahren.

Gerade die Möglichkeit zur Einleitung einer individualisierten Therapie auf Basis multidisziplinärer Befunde unterstreicht den Stellenwert der gemeinsamen Diskussion der Patienten im Rahmen von Tumorboards.

 

  • Literatur

  • 1 Joensuu H, Fletcher C, Dimitrijevic S et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-664
    CrossrefPubMedGoogle Scholar
  • 2 Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632
    CrossrefPubMedGoogle Scholar
  • 3 Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625
    CrossrefPubMedGoogle Scholar
  • 4 Demetri G, Cathryn J, Rankin RSB et al. Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. J Clin Oncol 2014; (Suppl. 32)
    PubMedGoogle Scholar
  • 5 Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
    CrossrefPubMedGoogle Scholar
  • 6 https://www.dgho-onkopedia.de/de/onkopedia/leitlinien Gastrointestinale Stromatumore (GIST). 2011
    PubMed
  • 7 http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
    PubMed
  • 8 Novitsky YW, Kercher KW, Sing RF et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006; 243: 738-745 discussion 745–747
    CrossrefPubMedGoogle Scholar
  • 9 Agaimy A, Wunsch PH. Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009; 394: 375-381
    CrossrefPubMedGoogle Scholar
  • 10 Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013; 382: 973-983
    CrossrefPubMedGoogle Scholar
  • 11 Rutkowski P, Gronchi A, Hohenberger P et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 2013; 20: 2937-2943
    CrossrefPubMedGoogle Scholar
  • 12 Girotti P, Rolinger J, Kopp HG et al. Gastrointestinal stromal tumours bigger than 20 cm: experience with imatinib chemotherapy in neoadjuvant intention. Z Gastroenterol 2014; 52: 50-54
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Joensuu H, Vehtari A, Riihimaki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274
    CrossrefPubMedGoogle Scholar
  • 14 Lagarde P, Perot G, Kauffmann A et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 826-838
    CrossrefPubMedGoogle Scholar
  • 15 Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465
    Google Scholar
  • 16 Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-1419
    CrossrefPubMedGoogle Scholar
  • 17 Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83
    CrossrefPubMedGoogle Scholar
  • 18 Gold JS, Gonen M, Gutierrez A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-1052
    CrossrefPubMedGoogle Scholar
  • 19 Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104
    CrossrefPubMedGoogle Scholar
  • 20 Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-1272
    CrossrefPubMedGoogle Scholar
  • 21 Huss S, Kunstlinger H, Wardelmann E et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol 2013; 26: 1004-1012
    CrossrefPubMedGoogle Scholar
  • 22 Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-878
    PubMedGoogle Scholar
  • 23 Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103
    CrossrefPubMedGoogle Scholar
  • 24 Emile JF, Brahimi S, Coindre JM et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012; 29: 1765-1772
    CrossrefPubMedGoogle Scholar
  • 25 Cassier PA, Fumagalli E, Rutkowski P et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-4464
    CrossrefPubMedGoogle Scholar
  • 26 Bardsley MR, Horvath VJ, Asuzu DT et al. Kitlow stem cells cause resistance to Kit / platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139: 942-952
    CrossrefPubMedGoogle Scholar
  • 27 Le Cesne A, Ray-Coquard I, Bui BN et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-949
    CrossrefPubMedGoogle Scholar
  • 28 Agaram NP, Besmer P, Wong GC et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 2007; 13: 170-181
    CrossrefPubMedGoogle Scholar
  • 29 Patrikidou A, Chabaud S, Ray-Coquard I et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013; 24: 1087-1093
    CrossrefPubMedGoogle Scholar
  • 30 Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134
    CrossrefPubMedGoogle Scholar
  • 31 Druker BJ, Guilhot F, OʼBrien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417
    CrossrefPubMedGoogle Scholar
  • 32 Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014; 89: 547-556
    CrossrefPubMedGoogle Scholar
  • 33 Corless CL. Gastrointestinal stromal tumors: what do we know now?. Mod Pathol 2014; 27 Suppl 1: S1-16
    CrossrefPubMedGoogle Scholar
  • 34 Hislop J, Mowatt G, Sharma P et al. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable / metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer 2012; 43: 168-176
    PubMedGoogle Scholar
  • 35 Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338
    CrossrefPubMedGoogle Scholar
  • 36 Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359
    CrossrefPubMedGoogle Scholar
  • 37 Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006; 368: 1303-1304
    CrossrefPubMedGoogle Scholar
  • 38 Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255
    CrossrefPubMedGoogle Scholar
  • 39 Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302
    CrossrefPubMedGoogle Scholar
  • 40 Kang YK, Ryu MH, Yoo C et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14: 1175-1182
    CrossrefPubMedGoogle Scholar
  • 41 Le Cesne A, Blay JY, Bui BN et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010; 46: 1344-1351
    CrossrefPubMedGoogle Scholar
  • 42 Soria JC, Massard C, Magne N et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and / or metastatic solid cancers. Eur J Cancer 2009; 45: 2333-2341
    CrossrefPubMedGoogle Scholar
  • 43 Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014; 6: 115-127
    CrossrefPubMedGoogle Scholar